Citations

Clear

361 citation(s) found for "Bauer, M".

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, Robert A. , Fuleihan, Ghada El‐Hajj , Bauer, Douglas C. , Camacho, Pauline M., Clines, Gregory A. , Edwards, Beatrice J. , Favus, Murray J., Greenspan, Susan L., McKinney, Ross E. , Pignolo, Robert J. , Sellmeyer, Deborah E. , Clarke, Bart L, Drake, Matthew T. , Clarke, B.L. , Compston, Juliet , Bauer, Douglas C , El-Hajj Fuleihan, Ghada

Mayo Clinic

Journal of Bone and Mineral Research | September 9, 2015 | Volume: 31 | Issue: 1 | Pages: 16-35

10.1002/jbmr.2708 | PMID 26350171 Get It

ABSTRACT Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fractures compared with those switched to placebo after 3 years. Low hip T-score, between –2 and –2.5 in FLEX and below –2.5 in HORIZON extension, predicted a beneficial response to continued therapy. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women at high risk, for example, older women, those with a low hip T-score or high fracture risk score, those with previous major osteoporotic fracture, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be considered. The risk of atypical femoral fracture, but not osteonecrosis of the jaw, clearly increases with BP therapy duration, but such rare events are outweighed by vertebral fracture risk reduction in high-risk patients. For women not at high fracture risk after 3 to 5 years of BP treatment, a drug holiday of 2 to 3 years can be considered. The suggested approach for long-term BP use is based on limited evidence, only for vertebral fracture reduction, in mostly white postmenopausal women, and does not replace the need for clinical judgment. It may be applicable to men and patients with glucocorticoid-induced osteoporosis, with some adaptations. It is unlikely that future trials will provide data for formulating definitive recommendations. © 2015 American Society for Bone and Mineral Research.
C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits
Chew, Jeannie , Prudencio, Mercedes , Sasaguri, Hiroki , Zhang, Yong‐Jie , Castanedes‐Casey, Monica , Lee, Chris W. , Jansen‐West, Karen , Kurti, Aishe, Murray, Melissa E. , Bieniek, Kevin F. , Bauer, Peter , Whitelaw, Ena C., Rousseau, Linda , Stankowski, Jeannette N. , Stetler, Caroline, Daughrity, Lillian M. , Perkerson, Emilie A., Desaro, Pamela , Johnston, Amelia, Overstreet, Karen, Edbauer, Dieter , Rademakers, Rosa , Fryer, John Denis , Petrucelli, Leonard , Gendron, Tania F. , Castanedes-Casey, Monica, Jansen-West, Karen, Bauer, Peter O, Boylan, Kevin B, Fryer, John D., Boylan, Khrista , Dickson, Dennis W. , Zhang, Yong-Jie , Prudencio, Mercedes , Murray, Melissa E

Mayo Clinic

Science | May 14, 2015 | Volume: 348 | Issue: 6239 | Pages: 1151-1154

10.1126/science.aaa9344 | PMID 25977373 Get It

A mouse model for ALS A G4C2 repeat expansion in C9ORF72 is known to be the major genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis (c9FTD/ALS). However, a lack of animal models recapitulating key disease features has hindered efforts to understand and prevent c9FTD/ALS-related neurodegeneration. Until now. Chew et al. describe a mouse model that mimics both neuropathological and clinical phenotypes of c9FTD/ALS. Science , this issue p. 1151
Quantitative Real-Time PCR Analysis of YKL-40 and Its Comparison with Mammalian Chitinase mRNAs in Normal Human Tissues Using a Single Standard DNA
Ohno, Misa, Bauer, Peter , Kida, Yuta, Sakaguchi, Masayoshi , Sugahara, Yasusato, Oyama, Fumitaka , Bauer, Peter O

Mayo Clinic

International Journal of Molecular Sciences | April 30, 2015 | Volume: 16 | Issue: 5 | Pages: 9922-9935

10.3390/ijms16059922 | PMID 25941933 Get It

YKL-40 (YKL for the first three N-terminal residues of a 40 kDa protein) belongs to a group of human chitinase-like proteins (CLPs), which are similar to chitinases but lack chitinolytic activity. YKL-40 mRNA and its protein levels have been reported elevated in multiple disorders including asthma, cystic fibrosis, rheumatoid arthritis and malignant tumors. Here, we quantified the YKL-40 mRNA levels and compared them with chitinases and housekeeping genes in normal human tissues. To establish the quantitative real-time PCR (qPCR) system for evaluation of relative YKL-40 mRNA levels, we constructed a human standard DNA molecule by ligating cDNAs of YKL-40, two mammalian chitinases and two housekeeping genes in a one-to-one ratio. We generated cDNAs from various normal human tissues and analyzed the YKL-40 mRNA expression levels using a qPCR system with the standard DNA. We found that YKL-40 mRNA is present widely in human tissues while its expression patterns exhibit clear tissue specificity. Highest YKL-40 mRNA levels were detected in the liver, followed by kidney, trachea and lung. The levels of YKL-40 mRNA in the kidney and liver were more than 100-times higher than those of chitotriosidase mRNA. Our study provides for the first time a comprehensive analysis of the relative expression levels of YKL-40 mRNA versus mammalian chitinases in normal human tissues.
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Francis, Gary L., Waguespack, Steven G. , Benvenga, Salvatore , Cerutti, Janete M. , Hamilton, Jill , Luster, Markus , Parisi, Marguerite T. , Rachmiel, Marianna , Thompson, Geoffrey B. , Yamashita, Shunichi , Hay, Ian D. , Bauer, Andrew J , Angelos, Peter , Dinauer, Catherine , Hay, Ian

Mayo Clinic

Thyroid® | April 21, 2015 | Volume: 25 | Issue: 7 | Pages: 716-759

10.1089/thy.2014.0460 | PMID 25900731 Get It

Background: Previous guidelines for the management of thyroid nodules and cancers were geared toward adults. Compared with thyroid neoplasms in adults, however, those in the pediatric population exhibit differences in pathophysiology, clinical presentation, and long-term outcomes. Furthermore, therapy that may be recommended for an adult may not be appropriate for a child who is at low risk for death but at higher risk for long-term harm from overly aggressive treatment. For these reasons, unique guidelines for children and adolescents with thyroid tumors are needed. Methods: A task force commissioned by the American Thyroid Association (ATA) developed a series of clinically relevant questions pertaining to the management of children with thyroid nodules and differentiated thyroid cancer (DTC). Using an extensive literature search, primarily focused on studies that included subjects ≤18 years of age, the task force identified and reviewed relevant articles through April 2014. Recommendations were made based upon scientific evidence and expert opinion and were graded using a modified schema from the United States Preventive Services Task Force. Results: These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules. Recommendations for the evaluation, treatment, and follow-up of children and adolescents with DTC are outlined and include preoperative staging, surgical management, postoperative staging, the role of radioactive iodine therapy, and goals for thyrotropin suppression. Management algorithms are proposed and separate recommendations for papillary and follicular thyroid cancers are provided. Conclusions: In response to our charge as an independent task force appointed by the ATA, we developed recommendations based on scientific evidence and expert opinion for the management of thyroid nodules and DTC in children and adolescents. In our opinion, these represent the current optimal care for children and adolescents with these conditions.
Acupuncture in the Postoperative Setting for Breast Cancer Patients: A Feasibility Study
Mallory, Molly J., Croghan, Katrina, Sandhu, Nicole P. , Lemaine, Valérie, Bauer, Brent A. , Cha, Stephen S., Croghan, Ivana T. , Degnim, Amy C. , Cha, Stephen S.

Mayo Clinic

The American Journal of Chinese Medicine | February 16, 2015 | Volume: 43 | Issue: 01 | Pages: 45-56

10.1142/s0192415x15500032 | PMID 25682785 Get It

Acupuncture is used to treat a variety of symptoms and conditions associated with cancer and cancer treatments. The present study was performed to evaluate the feasibility of providing acupuncture in the hospital setting for breast cancer patients and to evaluate the short-term effect of acupuncture on stress, anxiety, and pain. This was an open label study conducted at Mayo Clinic Hospital, Methodist and Saint Marys Campus, Rochester, Minnesota. A total of 20 adult breast cancer patients undergoing mastectomy and/or breast reconstruction were recruited and offered daily acupuncture intervention beginning postoperative day 1 and continuing for the duration of the hospital stay. Outcome measures included the Symptom Visual Analog Scale (VAS) and Satisfaction Question and Was-it-Worth-it (WIWI) Questionnaire. It was found that acupuncture is a feasible option for postoperative breast cancer patients. In addition, it can significantly decrease the levels of anxiety (p = 0.0065), tension/muscular discomfort (p < 0.001) and pain (p = 0.023). The association between acupuncture and relaxation was found to be statistically borderline (p = 0.053). This feasibility study showed that acupuncture can be integrated into a busy postsurgical clinical practice. These results also suggest that acupuncture may be an important intervention in the postoperative setting for breast cancer patients.
Functional Properties of the Catalytic Domain of Mouse Acidic Mammalian Chitinase Expressed in Escherichia coli
Kashimura, Akinori, Kimura, Masahiro , Okawa, Kazuaki , Suzuki, Hirotaka , Ukita, Atsushi, Wakita, Satoshi , Okazaki, Kana, Ohno, Misa, Bauer, Peter , Sakaguchi, Masayoshi , Sugahara, Yasusato, Oyama, Fumitaka , Bauer, Peter O

Mayo Clinic

International Journal of Molecular Sciences | February 13, 2015 | Volume: 16 | Issue: 2 | Pages: 4028-4042

10.3390/ijms16024028 | PMID 25689423 Get It

Mouse acidic mammalian chitinase (AMCase) plays important physiological roles in defense and nutrition. AMCase is composed of an N-terminal catalytic domain (CatD) and a C-terminal chitin-binding domain (CBD). We expressed CatD of mouse AMCase as a recombinant fusion protein with Protein A and V5-His in Escherichia coli (Protein A-CatD-V5-His), evaluated its functional properties and compared them to the full-length AMCase (Protein A-AMCase-V5-His). Under our experimental conditions, the chitinolytic activity of both proteins against 4-nitrophenyl N,N'-diacetyl-β-d-chitobioside was equivalent with regard to their specific enzymatic activities, optimal pH and temperature as well as to the pH and temperature stability. CatD bound to chitin beads and cleaved the N-acetylglucosamine hexamer, colloidal and crystalline chitin as well as the shrimp shell, and released primarily N,N'-diacetylchitobiose fragments at pH 2.0. These results indicate that the primary structure of CatD is sufficient to form a proper tertiary structure required for chitinolytic activity, recognize chitin substrates and degrade them in the absence of a CBD. Our recombinant proteins can be used for further studies evaluating pathophysiological roles of AMCase in different diseases.
Atrioventricular Node Ablation in Langendorff-Perfused Porcine Hearts Using Carbon Ion Particle Therapy
Richter, Daniel , Prokesch, Hannah, Graeff, Christian , Prall, Matthias, Simoniello, Palma , Fournier, Claudia , Bauer, Julia , Kaderka, Robert, Weymann, Alexander , Szabó, Gábor , Sonnenberg, Karin, Constantinescu, A., Johnson, Susan B., Misiri, Juna, Takami, Mitsuru , Miller, Robert C. , Herman, Michael , Asirvatham, Samuel J. , Jäkel, Oliver , Haberer, Thomas, Durante, Marco , Bert, Christoph , Packer, Douglas L. , Lehmann, H. Immo , Constantinescu, Anna M, Herman, Michael G., Brons, Stephan, Debus, Jürgen, Sonnenberg, Karin, Brons, Stephan , Debus, Jürgen , Bert, Christoph , Durante, Marco , Graeff, Christian , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | January 22, 2015 | Volume: 8 | Issue: 2 | Pages: 429-438

10.1161/circep.114.002436 | PMID 25609687 Get It

Background— Particle therapy, with heavy ions such as carbon-12 ( 12 C), delivered to arrhythmogenic locations of the heart could be a promising new means for catheter-free ablation. As a first investigation, we tested the feasibility of in vivo atrioventricular node ablation, in Langendorff-perfused porcine hearts, using a scanned 12C beam. Methods and Results— Intact hearts were explanted from 4 (30–40 kg) pigs and were perfused in a Langendorff organ bath. Computed tomgraphic scans (1 mm voxel and slice spacing) were acquired and 12 C ion beam treatment planning (optimal accelerator energies, beam positions, and particle numbers) for atrioventricular node ablation was conducted. Orthogonal x-rays with matching of 4 implanted clips were used for positioning. Ten Gray treatment plans were repeatedly administered, using pencil beam scanning. After delivery, positron emission tomography-computed tomgraphic scans for detection of β + ( 11 C) activity were obtained. A 12 C beam with a full width at half maximum of 10 mm was delivered to the atrioventricular node. Delivery of 130 Gy caused disturbance of atrioventricular conduction with transition into complete heart block after 160 Gy. Positron emission computed tomgraphy demonstrated dose delivery into the intended area. Application did not induce arrhythmias. Macroscopic inspection did not reveal damage to myocardium. Immunostaining revealed strong γH2AX signals in the target region, whereas no γH2AX signals were detected in the unirradiated control heart. Conclusions— This is the first report of the application of a 12 C beam for ablation of cardiac tissue to treat arrhythmias. Catheter-free ablation using 12C beams is feasible and merits exploration in intact animal studies as an energy source for arrhythmia elimination.
Acupuncture Treatment of Diplopia Associated with Abducens Palsy: A Case Report
Do, Alexander , Wahner‐Roedler, Dietlind L. , Bauer, Brent A.

Mayo Clinic

Global Advances in Health and Medicine | December 30, 2014 | Volume: 3 | Issue: 4 | Pages: 32-34

10.7453/gahmj.2014.024 | PMID 25105074 Get It

Abducens palsy (ie, sixth nerve palsy) is the most common single extraocular muscle palsy. The primary symptom is double vision. The treatment goal is to correct the underlying cause. If no cause is identified or the palsy is related to a well-managed chronic disease, treatment consists of patching one eye or applying a temporary prism. We report a patient whose abducens palsy resolved with four acupuncture treatments. The patient, a 58-year-old Vietnamese man with diabetes mellitus, presented to our institution's ophthalmology department with sudden onset of double vision. Ophthalmologic examination resulted in diagnosis of isolated left abducens palsy. The patient received a temporary prism for symptomatic relief. With no improvement after 2 months, he presented to our integrative medicine program inquiring about acupuncture. He received four acupuncture treatments over 11 weeks with complete resolution of his diplopia. This case is suggestive that acupuncture may be helpful treatment of patients with abducens palsy.
The EADC‐ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity
Frisoni, Giovanni B. , Jack, Clifford R. , Bocchetta, Martina , Frederiksen, Kristian Steen , Liu, Yawu , Preboske, Gregory M., Swihart, Tim, Blair, Melanie , Cavedo, Enrica , Grothe, Michel J. , Lanfredi, Mariangela , Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis , Ward, Chadwich, Apostolova, Liana G. , Ganzola, Rossana , Barkhof, Frederik , Bartzokis, George, DeCarli, Charles , Csernansky, John G., deToledo‐Morrell, Leyla, Geerlings, Mirjam I. , Lehéricy, Stéphane , O’Brien, John T. , Silbert, Lisa C. , Scheltens, Philip , Waldemar, Gunhild, Fellgiebel, Andreas , Barnes, Josephine , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pruessner, Jens C. , Watson, Craig, Leon, Mony J. de , Pantel, Johannes, Ferrari, Clarissa , Bosco, Paolo , Pasqualetti, Patrizio , Duchesne, Simon , Duvernoy, Henri M., Boccardi, Marina , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Albert, Marilyn S. , Bennet, David, Camicioli, Richard , Collins, D. Louis , Dubois, Bruno , Hampel, Harald , denHeijer, Tom, Hock, Christofer, Jagust, William J. , Launer, Leonore J., Maller, Jerome J. , Mueller, S. G., Sachdev, Perminder S. , Simmons, Andy, Visser, Peter‐Jelle, Wahlund, Lars‐Olof , Weiner, Michael W. , Winblad, Bengt , Boccardi, Marina , Frisoni, Giovanni B. , DeCarli, Charles , Preboske, Gregory, Bauer, Corinna M. , Wolf, Dominik Georg Friedrich , Kaye, Jeffrey , Killiany, Ronald , Matsuda, Hiroshi , O'Brien, John Tiernan , Soininen, Hilkka S. , Teipel, Stefan Johannes , Waldemar, Gunhild , Firbank, Michael John , Wang, Lei , Wolf, Henrike , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Thompson, Paul M. , Jack, Clifford R , Sachdev, Perminder S , Barkhof, Frederik , Scheltens, Philip , Wahlund, Lars-Olof , Grothe, Michel J , Bocchetta, Martina , Stoub, Travis

Mayo Clinic

Alzheimer's & Dementia | September 27, 2014 | Volume: 11 | Issue: 2 | Pages: 111-125

10.1016/j.jalz.2014.05.1756 | PMID 25267715 Get It

Abstract Background An international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance. Methods Fourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web‐platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T. Results The agreement among tracers was relatively low with the local protocols (absolute left/right ICC 0.44/0.43) and much higher with the HarP (absolute left/right ICC 0.88/0.89). On the larger set of 15 cases, the HarP agreement within (left/right ICC range: 0.94/0.95 to 0.99/0.99) and among tracers (left/right ICC range: 0.89/0.90) was very high. The volume variance due to different tracers was 0.9% of the total, comparing favorably to variance due to scanner manufacturer (1.2), atrophy rates (3.5), hemispheric asymmetry (3.7), field strength (4.4), and significantly smaller than the variance due to atrophy (33.5%, P < .001), and physiological variability (49.2%, P < .001). Conclusions The HarP has high measurement stability compared with local segmentation protocols, and good reproducibility within and among human tracers. Hippocampi segmented with the HarP can be used as a reference for the qualification of human tracers and automated segmentation algorithms.